Candel Therapeutics Announces Initial Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer
Initial positive interim data revealed notable improvements in patients with borderline resectable pancreatic ductal adenorcarcinoma after experimental treatment with CAN-2409 Estimated overall...
Source: marketscreener.com